분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-08-07 23:26:03 , Hit : 737
 Resistance to HIV Engineered Via CRISPR

The Scientist »
News & Opinion »
Daily News

Mice transplanted with human hematopoietic stem cells that have an HIV receptor gene, CCR5, disrupted by gene editing allows the animals to ward off HIV infection.

By Anna Azvolinsky | August 3, 2017

http://www.the-scientist.com/?articles.view/articleNo/50018/title/Resistance-to-HIV-Engineered-Via-CRISPR/&utm_campaign=NEWSLETTER_TS_The-Scientist-Daily_2016&utm_source=hs_email&utm_medium=email&utm_content=55018669&_hsenc=p2ANqtz-9JBWKmxdQbqY3kAgsFu3PhFu_lFPXFdKEMtaP8J5GS2BDbyWi57GhwqjAJOIYbA5gZxBvJzXck6W_LORkTn0Bc83VePQ&_hsmi=55018669


A minor proportion of people harbor a homozygous mutation in CCR5—a gene that encodes a receptor found on immune cells—that thwarts HIV’s attempts to get inside the cells. In an attempt to mimic this natural resistance, researchers mutated CCR5 in human fetal liver hematopoietic stem/progenitor cells (HSPCs) and showed that the cells could block HIV infection after transplantation into mice.

“These are expected observations that support prior data that targeting CCR5 can impede HIV replication and spread,” says neuroscientist Kamel Khalili who studies HIV infection at Temple University’s Lewis Katz School of Medicine in Philadelphia and who was not involved in the study. “CRISPR may be more convenient for gene editing than the prior gene editing tools used.”

The study is not the first to use gene editing to interrupt the CCR5 gene in human hematopoietic stem/progenitor cells. In a study published in 2010, Paula Cannon and her colleagues used zinc-finger nucleases to disrupt the gene and showed that the edited cells, when engrafted into mice, could clonally expand and retain the CCR5 deletion. This previous work has led to an on-going clinical trial to test this gene editing approach in HIV-infected individuals.  

With CRISPR, Khalili’s team previously cut out HIV from the human genome, yet there are also studies of how HIV could evade CRISPR-based anti-HIV therapy. There is yet no CRISPR-based gene editing system being tested in clinical trials in the United States.

See “How HIV Can Escape an Experimental CRISPR Therapy”

In the new work, published August 2 in Molecular Therapy, Hu Chen of the 307 Hospital of the Peoples Liberation Army, Hongkui Deng of the Peking University Stem Cell Research Center, both in Beijing, China, and their colleagues used CRISPR/Cas9 to disrupt CCR5 in CD34+ HSPCs. They demonstrated a 21 percent to 28 percent CCR5 editing efficiency, higher than the 17 percent efficiency reported using the zinc finger approach.

The work is the first to use CRISPR to achieve a long-lasting CCR5 mutation in HSCs in an animal model. “One of the advantages of CRISPR is its high efficiency on difficult to transfect cells,” write Deng and Chen in a joint email to The Scientist.


CCR5 seems to be the one Achilles heel of HIV. There may be some other targets but for now it’s the best target.—James Riley,
University of Pennsylvania

The authors were able to target a region of CCR5 that had significant differences with CCR2, a highly homologous gene subject to off-target effects using the zinc finger nuclease approach, notes James Riley, who studies how HIV infects T-cells at the University of Pennsylvania and who was not involved in the current study.    

The team showed that these CRISPR-edited HSPCs could be successfully engrafted into mice and that the cells could differentiate to form the spectrum of normal immune cell lineages over the course of 47 weeks. The CCR5-edited HSPCs from the engrafted mice could then be used for a secondary transplantation into another set of mice, the researchers showed.

“The long-term reconstitution and secondary transplantation were time-consuming. It took us more than one-year monitoring of the mice to confirm the gene editing is robust in long-term HSCs,” write Deng and Chen.

See “Genome Editing Cuts Out HIV”

Next, the researchers challenged either mice transplanted with CCR5-edited or non-edited human CD34+ HSPCs with an HIV strain that uses CCR5 to gain access to T-cells. In the mice harboring the mutated human stem cells, there was a decrease in HIV RNA in the first few weeks of infection and a smaller decline in CD4+ T-cells compared to animals transplanted with normal human HSPCs.  

“This is convincing evidence that CRISPR mediated deletion of CCR5 results in the intended resistance to the CD4+ progeny of the CCR5,” writes David DiGiusto, who directs Stanford University’s Laboratory for Cell and Gene Medicine and has helped development of the zinc finger approach for disrupting CCR5, in an email to The Scientist.

Still, it is unlikely that fetal liver stem cells will be used in human clinical trials, DiGiusto and Khalili agree. “Caution should be taken interpreting [these results] as generalizable to HSPCs from adult HIV patients,” writes DiGiusto.

A caveat to targeting CCR5, notes Khalili, is that this approach “may not be a complete cure because the virus itself is not eliminated and may shift to using the CCR4 or another receptor to spread.” Targeting CCR5 will also not protect against X4 tropic HIV isolates that use the CXCR4 receptor, rather than CCR5, to gain entry into immune cells.

Yet “CCR5 seems to be the one Achilles heel of HIV. There may be some other targets but for now it’s the best target,” says Riley.

Chen, Deng, and their colleagues are planning to start a clinical trial to test whether CRISPR/Cas9-mutated CCR5 in donor CD34+ hematopoietic stem/progenitor cells can be safely infused into HIV-infected individuals and could confer a level of resistance to HIV.

Writes DiGiusto, “the ongoing clinical trials that have been developed will begin to answer the feasibility and efficacy of targeting CCR5 for HIV infection.”

L. Xu et al., “CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo,” Molecular Therapy, doi.org/10.1016/j.ymthe.2017.04.027, 2017.







867   Protein synthesis: Stop the nonsense  이성욱 2011/06/20 2288
866   Regado Biosciences Kicks Off Big Clinical Trial For Heart Drug  이성욱 2013/09/18 3244
865   Regeneron to Use Avalanche Platform in $640M+ Gene Therapy Collaboration  이성욱 2014/05/07 1627
864   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2346
863   Rejected flies turn to booze  이성욱 2012/03/19 2649
862   Repeats protect DNA  이성욱 2010/02/06 4443
861   Reprogrammed cells trigger immune reactions in mice  이성욱 2011/05/20 2109
860   Reprogrammed human blood cells show promise for disease research  이성욱 2010/07/09 2225
859   Reprogrammed Stem Cells Are Rife with Mutations  이성욱 2011/03/04 2230
858   Research on Killer HIV Antibodies Provides Promising New Ideas for Vaccine Design-polyreactivity  이성욱 2010/10/05 2335
857   Research provides new findings on drug delivery with nanoparticles  이성욱 2011/03/07 2341
856   Researchers Develop Gene Therapy That Could Correct a Common Form of Blindness  이성욱 2012/01/27 2732
855   Researchers discover a switch that controls stem cell pluripotency  이성욱 2011/09/21 2318
854   Researchers discover mechanism that could convert certain cells into insulin-making cells  이성욱 2011/05/04 2642
853   Researchers identify potential molecular target to prevent growth of cancer cells  이성욱 2011/09/21 2351
852   Researchers Successfully Perform First Injection of Cultured Red Blood Cells in Human Donor  이성욱 2011/09/08 2348
851   Researchers turn adult cells back into stem cells  이성욱 2014/01/30 1621
850   Researchers uncover Fragile X syndrome gene's role in shaping brain  이성욱 2010/05/13 3062
849   Researchers: AIDS virus can hide in bone marrow  이성욱 2010/03/09 3194
  Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 737

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN